IP Library Granted Patent US 8,759,400
Granted Patent B2
US 8,759,400 · App. 11/641,615 · Granted Jun 24, 2014

Histone deacetylase inhibitors for enhancing activity of antifungal agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,400
App. No.
11/641,615
Granted
Jun 24, 2014
Kind
B2
Abstract

The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, this invention relates to compositions and methods for selectively enhancing fungal sensitivity to antifungal compounds.

Claims (34)

1. A composition comprising a selective and synergistic amount of

(i) a histone deacetylase inhibitor, or a hydrate, solvate, pharmaceutically acceptable salt thereof, wherein the histone deacetylase inhibitor is a compound of formula (A)

or a hydrate, solvate, or pharmaceutically acceptable salt thereof, wherein

R is alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, preferably cycloalkyl, aryl, heteroaryl or heterocyclyl, any of which maybe optionally substituted;

x is an integer from 0 to 5, wherein the chain of length x is optionally substituted and wherein one carbon atom of the chain of length x is optionally replaced with a heteroatom;

n is an integer from 0 to 2; and

Y is H;

with the provisos that when x is 4, n is not 2, and when x is 3, n is not 3;

(ii) an antifungal effective amount of an antifungal agent, wherein the antifungal agent is an azole; and

(iii) a pharmaceutically acceptable carrier,

wherein the selective and synergistic amount of a histone deacetylase inhibitor is not toxic to mammalian cells.

2. The composition of claim 1 , wherein the histone deacetylase inhibitor is selected from the group consisting of

and hydrates, solvates, pharmaceutically acceptable salts thereof.

3. The composition of claim 1 , wherein the histone deacetylase inhibitor is selected from the group consisting of

or a hydrate, solvate, pharmaceutically acceptable salt thereof.

4. The composition of claim 1 , wherein the histone deacetylase inhibitor is

or a hydrate, solvate, pharmaceutically acceptable salt thereof.

5. The composition of claim 1 , wherein the antifungal agent is selected from the group consisting of ketoconazole, itraconazole, fluconazole, voriconazole, posaconazole and ravuconazole.

6. A method of selectively sensitizing a fungal cell to an antifungal agent comprising contacting the cell with a selective sensitizing effective amount of a histone deacetylase inhibitor, or a hydrate, solvate, or pharmaceutically acceptable salt, thereof, wherein the selective sensitizing effective amount of the histone deacetylase inhibitor or hydrate, solvate, or pharmaceutically acceptable salt thereof, is synergistic with an antifungal effective amount of an antifungal agent, and wherein

(i) the histone deacetylase inhibitor is a compound of formula (A)

wherein

R is alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, preferably cycloalkyl, aryl, heteroaryl or heterocyclyl, any of which maybe optionally substituted;

x is an integer from 0 to 5, wherein the chain of length x is optionally substituted and wherein one carbon atom of the chain of length x is optionally replaced with a heteroatom;

n is an integer from 0 to 2; and

Y is H;

with the provisos that when x is 4, n is not 2, and when x is 3, n is not 3;

(ii) the antifungal agent is ketoconazole, fluconazole, itraconazole, or voriconazole; and

(iii) the fungal cell is a C. albicans, C. glabrata , or A. fumigatus cell.

7. The method of claim 6 , wherein the histone deacetylase inhibitor is selected from the group consisting of

8. The method of claim 6 , wherein the histone deacetylase inhibitor is selected from the group consisting of

9. A method of selectively sensitizing a fungal cell to an antifungal agent comprising contacting the cell with a selective sensitizing effective amount of a histone deacetylase inhibitor, or a hydrate, solvate, or pharmaceutically acceptable salt, thereof, wherein the selective sensitizing effective amount of the histone deacetylase inhibitor or hydrate, solvate, or pharmaceutically acceptable salt thereof, is synergistic with an antifungal effective amount of an antifungal agent, and wherein

(i) the histone deacetylase inhibitor is

(ii) the antifungal agent is ketoconazole, fluconazole, itraconazole, voriconazole, fenpropimorph, terbinafine, or nikkomycin; and

(iii) the fungal cell is a C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. krusei, A. fumigatus, C. lusitaniae, C. dubliniensis, A. flavus, A. niger, A. terreus, Pseudallescheria boydii, Fusarium sp, Paecilomyces lilacinus, Rhizopus arrhizus, Coccidioides immitis, Trichosporon, Mucor Sp., or Histoplasma cell.

Assignments (4)
CHANGE OF NAME Recorded Oct 27, 2010
From: METHYLGENE, INC.
To: 92229129 QUEBEC INC.
Reel/Frame 025200/0827 →
MERGER Recorded Oct 27, 2010
From: 7503547 CANADA INC.
To: METHYLGENE, INC.
Reel/Frame 025201/0647 →
CHANGE OF NAME Recorded Oct 19, 2010
From: 922209129 QUEBEC INC., (FORMERLY "METHYLGENE, INC.")
To: 7503547 CANADA, INC.
Reel/Frame 025159/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2007
From: GEORGOPAPAKAKOU, NAFSIKA; HU, WENQI; CAMPEOL, NADIA; BEDARD, JEAN; DEZIEL, ROBERT; AJAMIAN, ALAIN
To: METHYLGENE, INC.
Reel/Frame 019232/0667 →